Welcome to our dedicated page for TANDEM DIABETES CARE SEC filings (Ticker: TNDM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TANDEM DIABETES CARE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TANDEM DIABETES CARE's regulatory disclosures and financial reporting.
Form 4 filing: On 18-Jun-2025 Tandem Diabetes Care (TNDM) reported that director Joao Paulo Falcao Malagueira acquired 1,749 common shares on 16-Jun-2025 through the automatic settlement of previously granted restricted stock units (RSUs). The RSUs were awarded on 15-Jun-2022 under the company’s 2013 Stock Incentive Plan and vest in three equal annual instalments. No cash consideration was paid (exercise price $0).
Following the conversion, the director’s direct ownership increases to 13,699 TNDM shares. The transaction is coded “M,” indicating a routine equity award vesting rather than an open-market trade, and leaves no remaining derivative securities from this grant. The filing does not signal any strategic or operational changes at the company.